110 related articles for article (PubMed ID: 16086050)
1. [Treatment of refractory and relapsed acute lymphocytic leukemia in adults].
Bao L; Jiang B; Huang XJ; Wang DB; Qiu JY; Lu XJ; Lu J; Shi HX; Wang FR; Lu DP
Beijing Da Xue Xue Bao Yi Xue Ban; 2005 Aug; 37(4):355-7. PubMed ID: 16086050
[TBL] [Abstract][Full Text] [Related]
2. [Effect of modified FLAG regimen therapy on 33 patients with relapsed/refractory leukemia].
Meng FY; Yang LJ; Xu B; Liu XL; Zheng WY; Zhang Y; Huang F; Sun J; Liu QF
Ai Zheng; 2003 Dec; 22(12):1330-3. PubMed ID: 14693062
[TBL] [Abstract][Full Text] [Related]
3. Mitoxantrone and continuous infusion of cytosine arabinoside in refractory and relapsed acute lymphoblastic leukemia.
Liso V; Specchia G; Capalbo S; Pavone V; Iacobazzi A; Iaculli ML; Dione R; Pansini N
Acta Haematol; 1992; 87(1-2):54-7. PubMed ID: 1585771
[TBL] [Abstract][Full Text] [Related]
4. IDA-FLAG regimen for the therapy of primary refractory and relapse acute leukemia: a single-center experience.
Yavuz S; Paydas S; Disel U; Sahin B
Am J Ther; 2006; 13(5):389-93. PubMed ID: 16988532
[TBL] [Abstract][Full Text] [Related]
5. Outcomes of Substituting Oral Fludarabine for Intravenous Fludarabine in Combination with Cytarabine and Filgrastim for Treatment of Primary Refractory or Relapsed Acute Leukemias.
Demichelis-Gómez R; Crespo-Solís E; Pérez-Jacobo LF; Valencia-Rocha UR; Rosas-López A
Rev Invest Clin; 2015; 67(5):287-95. PubMed ID: 26696332
[TBL] [Abstract][Full Text] [Related]
6. Mito-flag as salvage therapy for relapsed and refractory acute myeloid leukemia.
Hänel M; Friedrichsen K; Hänel A; Herbst R; Morgner A; Neser S; Nicklisch M; Teich M; Ehninger G; Fiedler F
Onkologie; 2001 Aug; 24(4):356-60. PubMed ID: 11574763
[TBL] [Abstract][Full Text] [Related]
7. [Clinical study on fludarabine combined with cytarabine regimen in the treatment of patients with refractory and relapsed acute myeloid leukemia].
Yao YY; Zhu Q; Zou LF; Dou HJ; Chen YM; Tang Y; Hu JP
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2009 Jun; 17(3):774-6. PubMed ID: 19549406
[TBL] [Abstract][Full Text] [Related]
8. Fludarabine and cytosine arabinoside in the treatment of refractory or relapsed acute lymphocytic leukemia.
Suki S; Kantarjian H; Gandhi V; Estey E; O'Brien S; Beran M; Rios MB; Plunkett W; Keating M
Cancer; 1993 Oct; 72(7):2155-60. PubMed ID: 8374873
[TBL] [Abstract][Full Text] [Related]
9. FLAG (fludarabine, cytarabine, G-CSF) as a second line therapy for acute lymphoblastic leukemia with myeloid antigen expression: in vitro and in vivo effects.
Visani G; Tosi P; Zinzani PL; Manfroi S; Ottaviani E; Cenacchi A; Carrara P; Clavio M; Gobbi M; Tura S
Eur J Haematol; 1996 May; 56(5):308-12. PubMed ID: 8641405
[TBL] [Abstract][Full Text] [Related]
10. [Experience with fludarabine treatment and review of the literature].
Telek B; Rejtó L; Kiss A; Batár P; Reményi G; Rák K; Udvardy M
Orv Hetil; 2002 Jun; 143(24):1459-65. PubMed ID: 12138643
[TBL] [Abstract][Full Text] [Related]
11. [IDA-FLAG (idarubicin, fludarabine, high dosage cytarabine and G-CSF)--an effective therapy regimen in treatment of recurrent acute myelocytic leukemia in children and adolescents. Initial results of a pilot study].
Fleischhack G; Graf N; Hasan C; Ackermann M; Breu H; Zernikow B; Bode U
Klin Padiatr; 1996; 208(4):229-35. PubMed ID: 8926688
[TBL] [Abstract][Full Text] [Related]
12. Cladribine combined with high doses of arabinoside cytosine, mitoxantrone, and G-CSF (CLAG-M) is a highly effective salvage regimen in patients with refractory and relapsed acute myeloid leukemia of the poor risk: a final report of the Polish Adult Leukemia Group.
Wierzbowska A; Robak T; Pluta A; Wawrzyniak E; Cebula B; Hołowiecki J; Kyrcz-Krzemień S; Grosicki S; Giebel S; Skotnicki AB; Piatkowska-Jakubas B; Kuliczkowski K; Kiełbiński M; Zawilska K; Kłoczko J; Wrzesień-Kuś A;
Eur J Haematol; 2008 Feb; 80(2):115-26. PubMed ID: 18076637
[TBL] [Abstract][Full Text] [Related]
13. Daunorubicin, cytarabine and fludarabine (DAF) for remission induction in relapsed or refractory acute myeloid leukemia. Evaluation of safety, tolerance and early outcome--Polish Adult Leukemia Group (PALG) pilot study.
Hołowiecki J; Grosicki S; Kyrcz-Krzemien S; Skotnicki AB; Piatkowska-Jakubas B; Warzocha K; Seferynska I; Zdziarska B
Ann Hematol; 2008 May; 87(5):361-7. PubMed ID: 18074133
[TBL] [Abstract][Full Text] [Related]
14. Teniposide (VM-26) and continuous infusion cytosine arabinoside for initial induction failure in childhood acute lymphoblastic leukemia. A Pediatric Oncology Group pilot study.
Ochs J; Rivera GK; Pollock BH; Buchanan G; Crist W; Freeman AI
Cancer; 1990 Oct; 66(8):1671-7. PubMed ID: 2208021
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetic and pharmacodynamic studies of fludarabine and cytosine arabinoside administered as loading boluses followed by continuous infusions after a phase I/II study in pediatric patients with relapsed leukemias. The Children's Cancer Group.
Avramis VI; Wiersma S; Krailo MD; Ramilo-Torno LV; Sharpe A; Liu-Mares W; Kowck R; Reaman GH; Sato JK
Clin Cancer Res; 1998 Jan; 4(1):45-52. PubMed ID: 9516951
[TBL] [Abstract][Full Text] [Related]
16. Fludarabine, cytarabine, and mitoxantrone (FLAM) for the treatment of relapsed and refractory adult acute lymphoblastic leukemia. A phase study by the Polish Adult Leukemia Group (PALG).
Giebel S; Krawczyk-Kulis M; Adamczyk-Cioch M; Jakubas B; Palynyczko G; Lewandowski K; Dmoszynska A; Skotnicki A; Nowak K; Holowiecki J;
Ann Hematol; 2006 Oct; 85(10):717-22. PubMed ID: 16832677
[TBL] [Abstract][Full Text] [Related]
17. Liposomal daunorubicin, fludarabine, and cytarabine (FLAD) as bridge therapy to stem cell transplant in relapsed and refractory acute leukemia.
De Astis E; Clavio M; Raiola AM; Ghiso A; Guolo F; Minetto P; Galaverna F; Miglino M; Di Grazia C; Ballerini F; Marani C; Pastori G; Mitscheunig L; Cruciani F; Lovera D; Varaldo R; Ghiggi C; Lemoli RM; Bacigalupo A; Gobbi M
Ann Hematol; 2014 Dec; 93(12):2011-8. PubMed ID: 24989345
[TBL] [Abstract][Full Text] [Related]
18. [IDA-FLAG regimen in treatment of patients with refractory or relapsed acute leukemia].
Qian SX; Li JY; Wu HX; Zhang R; Hong M; Xu W; Qiu HX
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2009 Apr; 17(2):464-7. PubMed ID: 19379589
[TBL] [Abstract][Full Text] [Related]
19. Low-dose cytarabine and aclarubicin combined with granulocyte colony-stimulating factor for the treatment of relapsed or primary refractory acute lymphocytic leukemia: a retrospective study of 25 Chinese patients.
Xue SL; Cui HX; Zou JY; Xue MX; Tang XW; Zhang YM; Wu DP
Hematol Oncol; 2013 Dec; 31(4):206-12. PubMed ID: 23616245
[TBL] [Abstract][Full Text] [Related]
20. [A clinical observation of fludarabine-containing regimens in the treatment of low grade non-Hodgkin's lymphoma].
Lü SQ; Yang JM; Song XM; Chen L; Zhang WP; Ni X; Xu XQ; Wang JM
Zhonghua Zhong Liu Za Zhi; 2007 Sep; 29(9):710-2. PubMed ID: 18246806
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
